Schedule 13G ownership disclosure

Dyne Therapeutics Inc

COMMON STOCK · CUSIP: 26818M108

Event date: 2026-02-28

Filing-level shares
26,578,437
Percent of class
16.2%
  • T. Rowe Price Investment Management, Inc.

    Shares: 26,578,437 · Class: 16.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001897612-26-000307
Form type
SCHEDULE 13G/A
Filer
Dyne Therapeutics, Inc.
CIK
CIK 1818794
Filed
Mar 06, 2026
Reporting period
Feb 28, 2026
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub